Fig. 4
From: The SF3B1R625H mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1
Mutant SF3B1 altered DLG1 expression. ADLG1 mRNA expression (RNA-seq data and quantitative PCR) in SF3B1 mutant (n = 2) vs. wild-type (n = 13) human prolactinoma tumors. BDLG1 mRNA expression in Sf3b1 mutant (n = 3) versus wild-type (n = 3) GH3 cells. FPKM: Fragments per kilobase per million mapped fragments. The results are expressed as mean ± SD (Student’s t test, *P < 0.05, ****P < 0.0001). C Representative immunohistochemical staining for DLG1 in SF3B1 mutant and wild-type human prolactinoma tumors; scale bar: 50 μm. D Immunofluorescence staining for DLG1 in rat prolactinoma tumors stereotactically injected with Ad-null, Ad-SF3B1WT, and Ad-SF3B1R625H, respectively; scale bar: 50 μm